[1]吕天娇,李凌燕,张 弘,等.肾动脉主干加分支射频消融在难治性高血压治疗中的应用[J].介入放射学杂志,2020,29(09):879-882.
　Lv Tianjiao,LI Lingyan,ZHANG Hong,et al.Application of radiofrequency ablation of the main renal artery together with its branch in treating resistant hypertension[J].journal interventional radiology,2020,29(09):879-882.

点击复制

肾动脉主干加分支射频消融在难治性高血压治疗中的应用()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［1］ Esler MD， Krum H， Schlaich M， et al. Renal sympathetic denervation for treatment of drug- resistant hypertension： one- year results from the simplicity HTN- 2 randomized， controlled trial［J］. Circulation， 2012， 126：2976- 2982.
［2］ Symplicity HTN- 2 Investigators. Renal sympathetic denervation in patients with treatment- resistant hypertension（the symplicity HTN- 2 trial）： a randomized controlled trial［J］. Lancet， 2010，376： 1903- 1909.
［3］ Papademetriou V， Worthley S， Tsioufis C， et al. Catheter- based renal denervation for the treatment of patients with drug- resistant hypertension： EnligTHN I： three- month data of a first in man study using a multi- electrode radiofrequency ablation catheter［J］. Circulation， 2012， 125： A19523.
［4］ Bhatt DL， Kandzari DE， O’Neill WW， et al. A controlled trail of renal denervation for resistant hypertension［J］. N Engl J Med， 2014， 370：1393- 1401.
［5］ Bohm M， Mahfound F， Ukena C. First report of the global SYMPLICITY registry on the effect of renal artery denervation in patients with uncontrolled hypertension［J］. Hypertension， 2015， 65： 766- 774.
［6］ Kandzari DE， Bohm M， Mahfoud F， et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs： 6- month efficacy and safety results from the SPYRAL HTN- ON MED proof- of- concept randomised trial［J］. Lancet，2018， 391：2346- 2355.
［7］ Smith SM， Gong Y， Handberg E， et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension［J］. J Hypertens， 2014， 32： 635- 643.
［8］ 杨 宁， 程康安，李拥军. 去肾交感神经支配术与高血压［J］. 介入放射学杂志， 2012， 21：441- 446.
［9］ Krum H， Schlaich MP， Sobotka PA， et al. Percutaneous renal denervation in patients with treatment- resistant hypertension： final 3- year report of the Symplicity HTN- 1 study［J］. Lancet， 2014， 383： 622–629.
［10］ 潘 涛，郭金和，滕皋军. 经导管肾交感神经射频消融术临床研究进展［J］. 介入放射学杂志， 2015， 24：1113- 1118.
［11］ Mahfoud F， Tunev S， Ewen S， et al. Impact of lesion placement on efficacy and safety of catheter- based radiofrequency renal ednervation［J］. J Am Coll Cardiol， 2015， 66：1766- 1775.
［12］ Bohm M， Brilakis N， Mancia G， et al. TCT- 762 renal denervation treatment with the Symplicity Spyral multielectrode catheter： 6- month safety and blood pressure outcomes from the Global SYMPLICITY Registry［J］. J Am Coll Cardiol， 2016， 68（Suppl）： B308.
［13］ Fengler K， Ewen S， Hollriegel R， et al. Blood pressure response to main renal artery and combined main renal artery plus branch renal denervation in patients with resistant hypertension［J］. J Am Heart Assoc， 2017， 6： e006196.